Buzz: Teva Chairman Sol Barer is getting busy with a top-to-bottom rehab plan for a wounded giant
Rumors about big changes in the works for Teva are reaching a fever pitch.
Today we got confirmation of an earlier newspaper report that longtime CFO Eyal Desheh is headed out the door. That followed a report from Bloomberg that the company’s specialty cancer drug portfolio is being put on the market. And the rumor mill shows every sign of heating up even more in the wake of reports that the company is prepping thousands of job cuts after CEO Erez Vigodman left the company a little more than two months ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.